A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day on days 1, 2,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2013
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682338/
https://ncbi.nlm.nih.gov/pubmed/23591789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-466706
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares